Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Publikováno v:
Diseases of the Colon & Rectum; Jan2005, Vol. 48 Issue 1, p148-152, 5p
Autor:
Ghouti, Laurent, Houvenaeghel, Gilles, Moutardier, Vincent, Giovannini, Marc, Magnin, Valérie, Lelong, Bernard, Bardou, Valérie-Jeanne, Delpero, Jean-Robert
Publikováno v:
Diseases of the Colon & Rectum; Jan2005, Vol. 48 Issue 1, p16-22, 7p
Publikováno v:
Diseases of the Colon & Rectum; Jan2005, Vol. 48 Issue 1, p108-113, 6p
Autor:
Kelly, Steven, Yeo, James, Robertson, Greg M., Chapman, Bruce, Wells, J. Elisabeth, Frizelle, Frank A.
Publikováno v:
Diseases of the Colon & Rectum; Aug2004, Vol. 47 Issue 8, p1386-1389, 4p
Autor:
Sibylle Koletzko, Lissy de Ridder, Gábor Veres, Johanna C. Escher, Zrinjka Mišak, Jorge Amil Dias, Sanja Kolaček, Gigi Veereman-Wauters, Jean-François Rahier, John Fell, Petter Malmborg
Publikováno v:
Journal of Pediatric Gastroenterology and Nutrition, 54(6), 830-837. Lippincott Williams & Wilkins
Combined immunosuppression by immunomodulators and biological therapy has become standard in the medical management of moderate-to-severe inflammatory bowel disease (IBD) because of clearly demonstrated efficacy. Clinical studies, registries, and cas
Autor:
Frans van der Heide, Arie Dijkstra, Frans A. Albersnagel, Rinse K. Weersma, Elise M. van der Logt, Gerard Dijkstra, Jan H. Kleibeuker, Klaas Nico Faber, Wim J. Sluiter
Publikováno v:
Inflammatory Bowel Diseases, 15(8), 1199-1207. LIPPINCOTT WILLIAMS & WILKINS
Background: Smoking is a remarkable risk factor for inflammatory bowel disease (IBD). aggravating Crohn's disease (CD) while having beneficial effects On Ulcerative colitis (UC). We Studied the effects of active and passive smoking in Dutch IBD patie
Autor:
M. N. Tanzi, Y. K. L. Koda, Maria Oliva-Hemker, Johanna C. Escher, David D. Moore, M. Dubinksy, Simon Murch, B. Sandhu, B. Warner, Hans Hildebrand, Jeong Kee Seo
Publikováno v:
Journal of Pediatric Gastroenterology and Nutrition, 47(2), 266-272. Lippincott Williams & Wilkins
Johns Hopkins University School of Medicine, Baltimore, MD, {Erasmus Medical Center–Sophia Children’s Hospital, Rotterdam, The Netherlands, {Children, Youth, and Women’s Health Service, Adelaide, Australia, §Cedars-Sinai Medical Center, David
Autor:
Cor G. M. I. Baeten, Regina G. H. Beets-Tan, Stephan J. van der Hagen, Wim G. van Gemert, Peter B. Soeters, Maurice G. V. M. Russel
Publikováno v:
Diseases of the Colon & Rectum, 48(4), 758-767. LIPPINCOTT WILLIAMS & WILKINS
PURPOSE: This study was designed to assess the healing rate of complex perianal fistulas in Crohn's disease after a multistep strategy, including induction treatment with Infliximab in case of active proctitis, followed by definitive surgery. METHODS
Publikováno v:
Journal of Pediatric Gastroenterology and Nutrition, 36, 464-469. Lippincott Williams & Wilkins
Objectives: Treatment options for patients with Crohn disease (CD) have expanded, but the use of some of these options in pediatric patients remains controversial. The authors evaluate current trends in treatment and areas of consensus or controversy
Autor:
Cristina Saro, Ana Gutiérrez, José Luis Cabriada, E. Domènech, Valle Garcia, Joaquín Hinojosa, Xavier Aldeguer, Isabel Vera, Esther Garcia-Planella, Mireia Peñalva, Pere Vilar, Pilar Nos, Juan Luis Mendoza, Miguel Montoro, Javier P. Gisbert, Montserrat Andreu, Jesus Barrio, María Chaparro, Julián Panés, Olga Merino, Maria Esteve, M Barreiro-de, Fernando Muñoz
Publikováno v:
INFLAMMATORY BOWEL DISEASES
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Background: Adalimumab is an effective treatment for Crohn's disease (CD), but may also be associated with loss of response. Few reports provide insight into the durability of treatment of CD with adalimumab for periods longer than 12 months in clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03115f98d9e6289da2a5129e7b4ee860
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1594
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1594